Market Risers: Panthera Resources PLC, GlaxoSmithKline plc, Shire PLC, SSE PLC & Imperial Brands PLC

Panthera Resources Plc
[shareaholic app="share_buttons" id_name="post_below_content"]

The stock price for Panthera Resources PLC company symbol: LON:PAT has gained 110% or 1.43 points throughout today’s trading session so far. Investors seem confident during the session. The high for the period has peaked at 4.3 dropping as low as 2. The total volume of shares exchanged so far has reached 7,520,599 with the daily average number around 48,728. The stock 52 week high is 26.5 around 25.2 points difference from the previous days close and the 52 week low at 1 a difference of some 0.3 points. This puts the market cap at £1.85m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Panthera Resources PLC being recorded at Thursday, December 20, 2018 at 12:00:54 PM GMT with the stock price trading at 2.73 GBX.

 

The trading price for GlaxoSmithKline plc EPIC code: LON:GSK has stepped up 1.12% or 16.8 points throughout today’s trading session so far. Market buyers are a positive bunch during the trading session. The period high has peaked at 1521.2 dropping as low as 1471.8. The total volume of shares traded by this point was 4,004,006 whilst the daily average number of shares exchanged is just 13,394,716. The 52 week high for the shares is 1648.8 around 145.8 points difference from the previous close and the 52 week low at 1179.39 a difference of some 323.61 points. Market capitalisation for the company is £75,410.17m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Thursday, December 20, 2018 at 12:03:01 PM GMT with the stock price trading at 1519.8 GBX.

 

The stock price for AstraZeneca plc EPIC code: LON:AZN has risen 1.42% or 85 points during today’s session so far. Traders seem confident during this period. The periods high has already touched 6060 dropping as low as 5858. Volume total for shares traded during this period was 742,884 whilst the daily average number of shares exchanged is just 2,641,131. The 52 week high for the shares is 6432.48 which is 464.48 points in difference on the previous days close and a 52 week low being 4544.5 making a difference of 1423.5 points. Market capitalisation is now £76,718.12m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca plc being recorded at Thursday, December 20, 2018 at 12:03:24 PM GMT with the stock price trading at 6053 GBX.

 

The stock price for Shire PLC ticker lookup code: LON:SHP has moved up 2.17% or 96 points in today’s trading session so far. Market buyers are a positive bunch while the stock has been in play. Range high for the period has seen 4597 dipping to 4427.55. The volume total for shares traded up to this point was 6,145,252 while the average shares exchanged is 6,931,648. The 52 week high is 4827.75 about 395.75 points difference from the previous days close and the 52 week low at 2940.5 a difference of some 1491.5 points. The market capitalisation currently stands at £41,514.19m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Shire PLC being recorded at Thursday, December 20, 2018 at 12:03:16 PM GMT with the stock price trading at 4528 GBX.

 

The trading price for SSE PLC with company EPIC: LON:SSE has stepped up 1.01% or 10.75 points in today’s trading session so far. Buyers have stayed positive while the stock has been in play. The high for the period has reached 1075 meanwhile the session low reached 1048.5. The total volume traded so far comes to 599,284 with the daily average at 4,928,800. The 52 week high is 1449.5 which comes in at 390 points different to the previous business close and a 52 week low sitting at 1029.87 a difference of some 29.63 points. This puts the market cap at £10,983.95m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for SSE PLC being recorded at Thursday, December 20, 2018 at 12:03:12 PM GMT with the stock price trading at 1070.25 GBX.

 

Stock in Imperial Brands PLC with ticker code: LON:IMB has climbed 1.27% or 29.5 points throughout today’s trading session so far. Traders have stayed positive during this period. The periods high has already touched 2354.5 dipping to 2282.5. The total volume of shares traded by this point was 1,059,630 while the average shares exchanged is 3,123,190. A 52 week share price high is 3193.5 which is 874.5 points difference from the previous days close and putting the 52 week low at 2239.5 a difference of some 79.5 points. Market capitalisation for the company is £22,403.28m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Imperial Brands PLC being recorded at Thursday, December 20, 2018 at 12:03:23 PM GMT with the stock price trading at 2348.5 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
SSE CEO Alistair Phillips-Davies to retire in 2025, ending an 11-year tenure that transformed SSE into a leader in clean energy and net-zero initiatives.
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.
GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

Search

Search